Sarepta Therapeutics Inc
SRPT
View Detailed Chart
17.207USD
+0.157+0.92%
Market hours （ET）Quotes delayed by 15 min
1.68BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.92%
5 Days
-0.07%
1 Month
-21.10%
6 Months
-83.02%
Year to Date
-85.85%
1 Year
-86.31%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Hold
Current Rating
33.037
Target Price
+82.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 235.24M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -31.41, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 95.91M shares, decreasing 10.25% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 10.64M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.36.
News
Sarepta Surges Over 14% as FDA Lifts Shipping Ban; Wall Street Anticipates Doubling in Stock Price
TradingKey - Sarepta Therapeutics (SRPT.US) announced on Monday, July 28, that it has resumed shipments of its gene therapy Elevidys in the U.S., following an authorization from the U.S. Food and Drug Administration (FDA). The company's stock spiked over 20% on Tuesday, closing up 14.21% at $15.83,
TradingKeyWed, Jul 30
Sarepta down after pausing Elevidys shipments in US
Shares of Sarepta Therapeutics SRPT.O down 1.7% at $13.10; they fell nearly 8% in premarket trading
ReutersTue, Jul 22
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Ticker SymbolSRPT
CompanySarepta Therapeutics Inc
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Websitehttps://www.sarepta.com/
Related Instruments
+0.61%
-0.59%
+0.01%
-1.71%
-0.49%
+5.27%
-0.01%
-0.03%
+0.10%
-0.25%
+0.17%
+0.39%
-0.50%
+0.06%
-0.53%
-1.54%
+0.04%
-0.45%
+1.56%
+0.74%
